Status:
COMPLETED
Regulation of CCL18 by Corticosteroids in Severe Asthma
Lead Sponsor:
University Hospital, Lille
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
The majority of asthmatic patients are well controlled by inhaled corticosteroid treatment, however some severe asthma resist this treatment. CCL18 is a target gene for corticosteroids and its dysfunc...
Eligibility Criteria
Inclusion
- control subjects =
- non-atopic and non-smoking
- cutting to negative pneumoallergens,
- Total IgE levels less than 100 ku / L
- no clinical history of asthma
- without background treatment
- patients with intermittent asthma =
- being asymptomatic between asthma attacks,
- with symptoms less than once a week
- having a forced expiratory volume per second (FEV1) of at least 80% of the theoretical.
- treated by ß2 mimetics on demand and will not have inhaled corticosteroids.
- severe asthma insensitive to corticosteroid therapy =
- continuous or nearly continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)\] airway obstruction fixed with FEV1 ranging from less than 15% after 7 days of oral corticosteroid therapy to 40 mg / day of prednisolone;
- Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
- Severe corticosensitive asthma = continuous or near continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)\]
- reversibility of FEV1 after treatment with oral corticosteroids.
- Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
- controlled moderate asthma treated with inhaled corticosteroids \<1500μg equivalent of beclomethasone dipropionate and with: ß2 long-acting mimetics (or anti-leukotriene, or theophylline) for at least 6 months.
Exclusion
- existence of a chronic inflammatory pathology other than asthma
- active smoking
- pregnant or lactating women
- have received oral corticosteroid treatment in the previous 3 weeks,
- have received non-steroidal anti-inflammatory drugs (NSAIDs) in the previous 2 weeks.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT03779152
Start Date
February 1 2009
End Date
February 1 2017
Last Update
December 21 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Calmette, CHRU
Lille, France